Which has preferable valuation and earnings, FRMM or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than Forum Markets. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forum Markets $9.41M 9.68 -$450.52M -$36.07 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is FRMM or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% NLS Pharmaceutics N/A N/A N/A

Does the media prefer FRMM or NCEL?

In the previous week, Forum Markets had 6 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 10 mentions for Forum Markets and 4 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.72 beat Forum Markets' score of 0.62 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NCEL or ATRA?

Atara Biotherapeutics has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Atara Biotherapeutics $120.77M 0.60 $32.69M -$0.67 N/A

Which has preferable valuation & earnings, CRDF or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than Cardiff Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiff Oncology $590K 151.80 -$45.85M -$0.67 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Does the media prefer CRDF or NCEL?

In the previous week, NLS Pharmaceutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat NLS Pharmaceutics' score of 0.72 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, RANI or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than Rani Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rani Therapeutics $1.63M 49.32 -$29.67M -$0.41 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is RANI or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% NLS Pharmaceutics N/A N/A N/A

Does the media favor RANI or NCEL?

In the previous week, Rani Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 4 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.72 beat Rani Therapeutics' score of 0.69 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, BTMD or NCEL?

biote has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio biote $192.22M 0.43 $27.05M $0.44 4.98 NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Does the media prefer BTMD or NCEL?

In the previous week, biote and biote both had 4 articles in the media. biote's average media sentiment score of 1.37 beat NLS Pharmaceutics' score of 0.72 indicating that biote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NLS Pharmaceutics (NCEL) Competitors

$3.98 -0.02 (-0.50%)

As of 07/14/2026 04:00 PM Eastern

Compare

NCEL vs. FRMM, ATRA, CRDF, RANI, and BTMD

Should you buy NLS Pharmaceutics stock or one of its competitors? MarketBeat compares NLS Pharmaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NLS Pharmaceutics include Forum Markets (FRMM), Atara Biotherapeutics (ATRA), Cardiff Oncology (CRDF), Rani Therapeutics (RANI), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does NLS Pharmaceutics compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

In the previous week, Forum Markets had 6 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 10 mentions for Forum Markets and 4 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.72 beat Forum Markets' score of 0.62 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NLS Pharmaceutics has lower revenue, but higher earnings than Forum Markets.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$9.41M	9.68	-$450.52M	-$36.07	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

NLS Pharmaceutics' return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
NLS Pharmaceutics	N/A	N/A	N/A

Forum Markets currently has a consensus price target of $10.00, suggesting a potential upside of 47.06%. NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 477.89%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Forum Markets has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

4.1% of Forum Markets shares are owned by institutional investors. 25.2% of Forum Markets shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Forum Markets beats NLS Pharmaceutics on 7 of the 12 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

70.9% of Atara Biotherapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 477.89%. Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 18.16%. Given NLS Pharmaceutics' higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Atara Biotherapeutics	$120.77M	0.60	$32.69M	-$0.67	N/A

In the previous week, NLS Pharmaceutics had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.94 beat NLS Pharmaceutics' score of 0.72 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Atara Biotherapeutics	Positive

NLS Pharmaceutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. NLS Pharmaceutics' return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Summary

NLS Pharmaceutics beats Atara Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

NLS Pharmaceutics has lower revenue, but higher earnings than Cardiff Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	151.80	-$45.85M	-$0.67	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, NLS Pharmaceutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat NLS Pharmaceutics' score of 0.72 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NLS Pharmaceutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. NLS Pharmaceutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
NLS Pharmaceutics	N/A	N/A	N/A

Cardiff Oncology currently has a consensus price target of $7.50, suggesting a potential upside of 472.52%. NLS Pharmaceutics has a consensus price target of $23.00, suggesting a potential upside of 477.89%. Given NLS Pharmaceutics' higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

16.3% of Cardiff Oncology shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cardiff Oncology has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Summary

NLS Pharmaceutics beats Cardiff Oncology on 7 of the 13 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NLS Pharmaceutics has lower revenue, but higher earnings than Rani Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	49.32	-$29.67M	-$0.41	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, Rani Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 4 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.72 beat Rani Therapeutics' score of 0.69 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NLS Pharmaceutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
NLS Pharmaceutics	N/A	N/A	N/A

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 1,248.23%. NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 477.89%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Rani Therapeutics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Summary

Rani Therapeutics beats NLS Pharmaceutics on 7 of the 12 factors compared between the two stocks.

How does NLS Pharmaceutics compare to biote?

biote (NASDAQ:BTMD) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

biote has a net margin of 8.29% compared to NLS Pharmaceutics' net margin of 0.00%. NLS Pharmaceutics' return on equity of 0.00% beat biote's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
NLS Pharmaceutics	N/A	N/A	N/A

21.7% of biote shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

biote has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.43	$27.05M	$0.44	4.98
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, biote and biote both had 4 articles in the media. biote's average media sentiment score of 1.37 beat NLS Pharmaceutics' score of 0.72 indicating that biote is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

biote presently has a consensus target price of $2.75, indicating a potential upside of 25.57%. NLS Pharmaceutics has a consensus target price of $23.00, indicating a potential upside of 477.89%. Given NLS Pharmaceutics' higher probable upside, analysts plainly believe NLS Pharmaceutics is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

biote has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Summary

biote beats NLS Pharmaceutics on 10 of the 12 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCEL vs. The Competition

Export

Metric	NLS Pharmaceutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.38M	$3.02B	$6.85B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.43%
P/E Ratio	N/A	18.77	27.04	24.38
Price / Sales	N/A	344.35	524.25	92.59
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	2.50	4.20	10.80	6.33
Net Income	-$8.30M	$65.13M	$3.59B	$331.02M
7 Day Performance	-5.91%	-2.63%	-1.46%	-0.33%
1 Month Performance	24.38%	2.14%	2.82%	-1.29%
1 Year Performance	-81.91%	23.26%	28.59%	21.30%

NLS Pharmaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCEL NLS Pharmaceutics	3.6067 of 5 stars	$3.98 -0.5%	$23.00 +477.9%	-81.3%	$21.38M	N/A	N/A	6	Positive News Analyst Forecast Gap Up
FRMM Forum Markets	3.3281 of 5 stars	$6.11 +7.1%	$10.00 +63.8%	N/A	$88.79M	$9.41M	N/A	7	News Coverage Analyst Revision
ATRA Atara Biotherapeutics	2.6738 of 5 stars	$9.78 -4.7%	$9.50 -2.9%	-13.5%	$88.12M	$23.14M	N/A	330	Gap Down
CRDF Cardiff Oncology	3.7495 of 5 stars	$1.28 -5.6%	$7.50 +488.2%	-68.3%	$87.04M	$590K	N/A	20
RANI Rani Therapeutics	1.9247 of 5 stars	$0.69 -2.7%	$8.75 +1,168.1%	-7.1%	$85.23M	$1.63M	N/A	110	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. FRMM, ATRA, CRDF, RANI, and BTMD

How does NLS Pharmaceutics compare to Forum Markets?

Summary

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

Summary

How does NLS Pharmaceutics compare to Cardiff Oncology?

Summary

How does NLS Pharmaceutics compare to Rani Therapeutics?

Summary

How does NLS Pharmaceutics compare to biote?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. FRMM, ATRA, CRDF, RANI, and BTMD

How does NLS Pharmaceutics compare to Forum Markets?

Does the media prefer FRMM or NCEL?

Which has preferable valuation and earnings, FRMM or NCEL?

Is FRMM or NCEL more profitable?

Do analysts rate FRMM or NCEL?

Which has more risk & volatility, FRMM or NCEL?

Do insiders and institutionals hold more shares of FRMM or NCEL?

Summary

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

Do institutionals and insiders believe in NCEL or ATRA?

Do analysts rate NCEL or ATRA?

Which has more risk and volatility, NCEL or ATRA?

Which has preferable earnings and valuation, NCEL or ATRA?

Does the media refer more to NCEL or ATRA?

Is NCEL or ATRA more profitable?

Summary

How does NLS Pharmaceutics compare to Cardiff Oncology?

Which has preferable valuation & earnings, CRDF or NCEL?

Does the media prefer CRDF or NCEL?

Is CRDF or NCEL more profitable?

Do analysts prefer CRDF or NCEL?

Do institutionals and insiders hold more shares of CRDF or NCEL?

Which has more volatility and risk, CRDF or NCEL?

Summary

How does NLS Pharmaceutics compare to Rani Therapeutics?

Do insiders and institutionals hold more shares of RANI or NCEL?

Which has stronger earnings and valuation, RANI or NCEL?

Does the media favor RANI or NCEL?

Is RANI or NCEL more profitable?

Do analysts prefer RANI or NCEL?

Which has more volatility & risk, RANI or NCEL?

Summary

How does NLS Pharmaceutics compare to biote?

Is BTMD or NCEL more profitable?

Do institutionals and insiders believe in BTMD or NCEL?

Which has better valuation and earnings, BTMD or NCEL?

Does the media prefer BTMD or NCEL?

Do analysts recommend BTMD or NCEL?

Which has more volatility & risk, BTMD or NCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools